Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,082.07
(
-0.38%
)
US TECH 100
25,812.00
(
-0.23%
)
Dow Jones
49,313.78
(
-0.27%
)
Brent Oil
95.51
(
5.33%
)
Bitcoin
75,622.14
(
-0.36%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 74291

Thursday, 03/12/2009 4:44:09 AM

Thursday, March 12, 2009 4:44:09 AM

Post# of 257432
Agree that JNJ probably won’t counterbid for SGP; memory of the bidding war JNJ got into with BSX for Guidant is probably still fresh.

However, it would be negligent of JNJ to not attempt to gain the ex-US rights to Remicade/Golimumab. At the least, JNJ should be able to extract a decent-sized cash payment in return for waiving the right to go to binding arbitration.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today